Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Filters

Thorsten M Leucker

Showing results (31-40 of 71) with videos related to

Pageof 8
Sort By:
Atherosclerosis|August 8, 2025
Oxidized phospholipid dynamics in the early post-infarction period: Effects of PCSK9 inhibition with evolocumabMark Atallah, Tarek Harb, Nadim Nasrallah, et al.
Journal of Cardiovascular Pharmacology|September 13, 2024
Peroxisome Proliferator-Activated Receptor Gamma Regulates Interleukin-6-Induced Lipoprotein (a) Gene Expression in Human HepG2 CellsTarek Harb, Efthymios Ziogos, Núria Amat-Alarcon, et al.
Frontiers in Medicine|June 30, 2022
Plasma Proprotein Convertase Subtilisin/kexin Type 9 (PCSK9) in the Acute Respiratory Distress SyndromeThomas S Metkus, Bo Soo Kim, Steven R Jones, et al.
The American Journal of Cardiology|October 24, 2023
Early Initiation of PCSK9 Inhibitor Therapy Versus Placebo in Patients With Acute Coronary Syndrome: A Systematic Review and Meta-AnalysisGustavo B Justino, Leonardo B Justino, Margrit Elis Müller, et al.
Circulation. Cardiovascular Imaging|September 29, 2023
Rapid Improvement of Coronary Endothelial Function With PCSK9 Inhibition in People With HIV Is Associated With Reduced Lipoprotein (a) and Not LDL-cholesterolTarek Harb, Efthymios Ziogos, Michael Schär, et al.
Plos One|July 30, 2013
Impairment of endothelial-myocardial interaction increases the susceptibility of cardiomyocytes to ischemia/reperfusion injuryThorsten M Leucker, Zhi-Dong Ge, Jesse Procknow, et al.
Journal of Cardiovascular Computed Tomography|February 7, 2024
Recent advances in cardiovascular risk assessment: The added value of non-invasive anatomic imagingPooja V Selvam, Gowtham R Grandhi, Thorsten M Leucker, et al.
Scientific Reports|February 10, 2025
Vericiguat prevents high glucose-mediated impaired vascular smooth muscle cGMP production and vasorelaxationDavid Polhemus, Diego Almodiel, Tarek Harb, et al.
Journal of the American Heart Association|July 18, 2020
Evolocumab, a PCSK9-Monoclonal Antibody, Rapidly Reverses Coronary Artery Endothelial Dysfunction in People Living With HIV and People With DyslipidemiaThorsten M Leucker, Gary Gerstenblith, Michael Schär, et al.
American Journal of Preventive Cardiology|June 3, 2024
Expanded genetic testing in familial hypercholesterolemia-A single center's experienceEmily E Brown, Kathleen Byrne, Erin D Michos, et al.
Pageof 8

Showing results (31-40 of 71) with videos related to

Sort By:
Pageof 8
Atherosclerosis|August 8, 2025
Oxidized phospholipid dynamics in the early post-infarction period: Effects of PCSK9 inhibition with evolocumabMark Atallah, Tarek Harb, Nadim Nasrallah, et al.
Journal of Cardiovascular Pharmacology|September 13, 2024
Peroxisome Proliferator-Activated Receptor Gamma Regulates Interleukin-6-Induced Lipoprotein (a) Gene Expression in Human HepG2 CellsTarek Harb, Efthymios Ziogos, Núria Amat-Alarcon, et al.
Frontiers in Medicine|June 30, 2022
Plasma Proprotein Convertase Subtilisin/kexin Type 9 (PCSK9) in the Acute Respiratory Distress SyndromeThomas S Metkus, Bo Soo Kim, Steven R Jones, et al.
The American Journal of Cardiology|October 24, 2023
Early Initiation of PCSK9 Inhibitor Therapy Versus Placebo in Patients With Acute Coronary Syndrome: A Systematic Review and Meta-AnalysisGustavo B Justino, Leonardo B Justino, Margrit Elis Müller, et al.
Circulation. Cardiovascular Imaging|September 29, 2023
Rapid Improvement of Coronary Endothelial Function With PCSK9 Inhibition in People With HIV Is Associated With Reduced Lipoprotein (a) and Not LDL-cholesterolTarek Harb, Efthymios Ziogos, Michael Schär, et al.
Plos One|July 30, 2013
Impairment of endothelial-myocardial interaction increases the susceptibility of cardiomyocytes to ischemia/reperfusion injuryThorsten M Leucker, Zhi-Dong Ge, Jesse Procknow, et al.
Journal of Cardiovascular Computed Tomography|February 7, 2024
Recent advances in cardiovascular risk assessment: The added value of non-invasive anatomic imagingPooja V Selvam, Gowtham R Grandhi, Thorsten M Leucker, et al.
Scientific Reports|February 10, 2025
Vericiguat prevents high glucose-mediated impaired vascular smooth muscle cGMP production and vasorelaxationDavid Polhemus, Diego Almodiel, Tarek Harb, et al.
Journal of the American Heart Association|July 18, 2020
Evolocumab, a PCSK9-Monoclonal Antibody, Rapidly Reverses Coronary Artery Endothelial Dysfunction in People Living With HIV and People With DyslipidemiaThorsten M Leucker, Gary Gerstenblith, Michael Schär, et al.
American Journal of Preventive Cardiology|June 3, 2024
Expanded genetic testing in familial hypercholesterolemia-A single center's experienceEmily E Brown, Kathleen Byrne, Erin D Michos, et al.
Pageof 8